Paul Olivo

Venture Partner, Synchrony Bio

Paul Olivo

Venture Partner, Synchrony Bio

Dr. Paul D. Olivo, M.D., Ph.D., has been the Chief Scientific Officer of Apath, LLC since 2000 and served as its President. Dr. Olivo is an Entrepreneur-in-Residence at BioGenerator, where he previously served as a Senior Entrepreneur-in-Residence. He served as a Vice President of R&D at Apath, LLC and served as its President since 2000. Dr. Olivo led a successful effort to license Apath’s key hepatitis C virus patents to multiple diagnostic and pharmaceutical companies and led the development of a novel technology to develop antiviral drugs which was instrumental in the company’s receiving 18 federal grants totaling over $12 million from 1999 to 2007. He joined Apath in 1998. He served as a Senior Medical Director of Quidel Corporation. Prior to joining Quidel, Dr. Olivo served as a Senior Vice President of R&D at Diagnostic Hybrids, Inc., where he played a significant role in managing the company’s pipeline and intellectual property during the acquisition of Hybrids by Quidel Corporation in 2010. Dr. Olivo has 20 years experience in the biotechnology industry in key executive positions at both established and start-up companies. He also has over 25 years experience in molecular biology and virology. Dr. Olivo serves as Director at Common Place Holdings. He serves as a Member of Scientific Advisory Board at Kypha Inc. Dr. Olivo served as a Medical Chief Resident at University of Wisconsin since 1986. He joined the faculty at Washington University School of Medicine in 1989 in the Department of Internal Medicine, Division of Infectious Diseases. He serves as an Adjunct Professor of Washington University Medical School in St. Louis, Missouri in the Department of Molecular Microbiology. Dr. Olivo is the inventor of multiple U.S. and foreign patents and has extensive knowledge of the application of genetically engineered cells to medical diagnostics. Currently Dr. Olivo is focusing his efforts on working with institutions in the greater St. Louis area to promote startup companies in the life sciences. Dr. Olivo performed his postdoctoral training in molecular virology at the National Institute of Allergy and Infectious Diseases at the NIH. He was a postdoctoral fellow at the National Institutes of Health from 1986 to 1989 in the Laboratory of Viral Diseases in the laboratories of Dr. Bernard Moss and Dr. Mark Challberg. Dr. Olivo is a licensed physician and board-certified Internist. Dr. Olivo holds B.A. from the George Washington University in Washington, D.C. in Anthropology and his M.D. in 1981 and Ph.D. in Microbiology in 1982 from the University of Florida. He received his medical training in Internal Medicine at the University of Wisconsin.

Consideration

With 2021 well underway and with public markets still strong, we think it is an important time to highlight some of the key private market, venture investment themes that iSelect fund has identified for the year. We believe technologies transforming the Agriculture, Food and Wellness markets will flourish, with a focus on four areas: technologies that enable better food choices to drive better health outcomes, technologies that drive better, more profitable farm operations, technologies that drive the Consumerization of Healthcare, and biome-based treatment technologies. At iSelect, we invest for impact AND performance. We offer qualified investors access to emerging growth companies through our national venture capital strategy. Our unique structure allows our investors to continue to invest in these companies as they develop.

Timing

Why is now the right time for venture? The answer is that now is not explicitly the right time. Venture is something we need in our economy at all times. Now is not better than any other particular time. The question is, why ever stop? When we look at the challenges we’re facing in food and healthcare the reality is there is someone, somewhere who has an insight about how to build a product that will solve those problems. And if they put the right resources to it, they will succeed. As long as we need new technology to make life better or make our lives more enjoyable, we need venture capital to help fuel those entrepreneurs.

What is iSelect as a product?

iSelect is a very unique product, but when you break it into its parts it’s fairly easy to understand. On the front end we’re a traditional venture capital fund. We have a diligence process. We have an investment process. We have categories of industries where we have focus and real expertise, and we invest in companies in those areas that meet requirements for the fund. On the back end we’re unique in that we don’t raise a large amount of capital at one time and deploy it over the life of our fund. Each deal that we bring onto the fund, our investors have to prove and determine to invest in that deal. We have to constantly prove our diligence standards. It’s accessible, transparent and easy for investors to come in and see our comprehensive process.

What is the ideal iSelect company?

We are looking for founders that are passionate and we want the problem they’re trying to solve to be big, real, and painful. We want the solution to be revolutionary and we want our capital to be able to help them solve that problem. We want to know that they have customers involved and that the solution they’ve come up with actually meets those customers’ and market needs. And we want the team to be capital efficient with the money they’re spending.

What does the ideal iSelect company look like?

We’re looking for a company that has an opportunity to have a 10x return to our investment or greater in a period of three to seven years. What excites us at iSelect are companies that are solving big problems. We want companies that are going to be the Monsantos of the future. Not just in the size and the scope, but the impact they have on people’s lives. We want to create positive impacts on people’s lives, so we invest in areas like agricultural production and areas like producing healthy foods for our kids. They are problems that impact real people’s lives on a daily basis. That’s what we’re trying to do at iSelect. We’re trying to solve the big problems out there. Find ways to bring capital to the entrepreneurs who are the real heroes out there getting up every morning, beating away at these things that are problems that you and me and everyone else faces in their everyday lives.

What is iSelect?

iSelect is a venture capital firm. What that means is we look at hundreds and hundreds of different companies and we apply tough diligence standards to each of them, looking at whether the team has a good plan for growing the business, whether the team is qualified and credible, and more. We do that to resolve the few who provide the best opportunities for investors. And then iSelect takes that smaller set of investments and goes to investors who are interested in venture capital and provides a way for them to invest in these companies, either individually or all at once. We co-invest alongside other venture capitalists. We source transactions through to an exit where the company would become public or get bought. And we manage that whole investment process on behalf of our investors.